drugset / Trial / NCT00369174

Rosiglitazone Maleate in Treating Patients With Oral Leukoplakia

NCT00369174

Phase 2 Completed 25 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelPrevention

Summary

This phase II trial is studying how well rosiglitazone works in preventing oral cancer in patients with oral leukoplakia. Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of rosiglitazone may keep cancer from forming in patients with oral leukoplakia

Timeline

Start
2006-06
Primary completion
2007-08
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Rosiglitazone Small molecule 8 mg Oral